Long-Term Outcome of Unrelated Donor Transplantation for AML Using Myeloablative Conditioning Incorporating Pretransplant Alemtuzumab

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 6, 2007, Pages 724-733

  Das Gupta, Emma P ^a   Russell, Nigel H ^a   Shaw, Bronwen E ^a   Pearce, Rachel M ^b   Byrne, Jennifer L ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b BSBMT Registry Cloudswood   (United Kingdom)

Author keywords

Alemtuzumab; Campath; MUD; Myeloablative

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOGENETICS; DONOR SELECTION; DRUG EFFICACY; FEMALE; HLA MATCHING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; OUTCOMES RESEARCH; OVERALL SURVIVAL; PREDICTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; FEMALE; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; LEUKEMIA, MYELOID; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 34248679012     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.02.011     Document Type: Article

References (39)

1. Heemskerk M.B., van Walraven S.M., Cornelissen J.J., et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!. Bone Marrow Transplant 35 (2005) 645-652
2. Petersdorf E.W., Anasetti C., Martin P.J., and Hansen J.A. Tissue typing in support of unrelated hematopoietic cell transplantation. Tissue Antigens 61 (2003) 1-11
3. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
4. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
5. Marsh J., Schrezenmeier H., Marin P., et al. Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood 93 (1999) 2191-2195
6. Byrne J.L., Stainer C., Cull G., et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia. Bone Marrow Transplant 25 (2000) 411-417
7. Finke J., Schmoor C., Lang H., Potthoff K., and Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 21 (2003) 506-513
8. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
9. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 35 (2005) 1011-1018
10. Remberger M., Storer B., Ringden O., and Anasetti C. Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. Bone Marrow Transplant 29 (2002) 391-397
11. Kalhs P., Brugger S., Reiter E., et al. Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. Bone Marrow Transplant 23 (1999) 753-758
12. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 30 (2002) 681-686
13. Finke J., Bertz H., Schmoor C., et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 111 (2000) 303-313
14. Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35 (2005) 225-231
15. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 3 (2001) 137-143
16. Novitzky N., Thomas V., Hale G., and Waldmann H. Campath-1 Abs "in the bag" for hematological malignancies: the Cape Town experience. Cytotherapy 6 (2004) 172-181
17. Marks D.I., Bird J.M., Vettenranta K., et al. T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 6 (2000) 646-653
18. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
19. Wheatley K., Burnett A.K., Goldstone A.H., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107 (1999) 69-79
20. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
21. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
22. Gray B. Subdistribution analysis of competing risks. R package version 2.1-5.2004. http://www.r-project.org, http://biowww.dfci.harvard.edu/∼gray.
23. Fine J.P., and Gray R.J. A proportional hazards model for the subdistribution of a competing risk. JASA 94 (1999) 496-509
24. Shaw B.E., Madrigal J.A., and Potter M. Improving the outcome of unrelated donor stem cell transplantation by molecular matching. Blood Rev 15 (2001) 167-174
25. Morishima Y., Sasazuki T., Inoko H., et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99 (2002) 4200-4206
26. Sierra J., Storer B., Hansen J.A., et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 26 (2000) 397-404
27. Greinix H.T., Loidolt H., Rabitsch W., et al. Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia. Ann Hematol 79 (2000) 206-213
28. Schiller G., Feig S.A., Territo M., et al. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors. Br J Haematol 88 (1994) 72-78
29. Dini G., Cancedda R., Locatelli F., et al. Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO). Haematologica 86 (2001) 451-456
30. Busca A., Anasetti C., Anderson G., et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 83 (1994) 3077-3084
31. Michallet M., Thomas X., Vernant J.P., et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 26 (2000) 1157-1163
32. Greinix H.T., Nachbaur D., Krieger O., et al. Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol 117 (2002) 914-923
33. Wong R., Giralt S.A., Martin T., et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood 102 (2003) 3052-3059
34. Martino R., Caballero M.D., Simon J.A., et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
35. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 23 (2005) 9387-9393
36. Scott B.L., Sandmaier B.M., Storer B., et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 20 (2006) 128-135
37. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19 (2005) 2304-2312
38. Burnett A.K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-An adult treater's view. Br J Haematol 118 (2002) 357-364
39. Burnett A.K., Hills R.K., Goldstone A.H., et al. The impact of transplant in AML in 2nd CR: a prospecive study of 741 in the MRC AML 10 and 12 trials. Blood (2004) 104 (Abstract).